| scholarly article | Q13442814 |
| P2093 | author name string | Bernard Zinman | |
| Hwee Teoh | |||
| Subodh Verma | |||
| Peter Jüni | |||
| Andrew T Yan | |||
| Paul Dorian | |||
| C David Mazer | |||
| Adrian Quan | |||
| Kim A Connelly | |||
| Lawrence A Leiter | |||
| Atul Verma | |||
| Ankit Garg | |||
| Fei Zuo | |||
| Andrew C T Ha | |||
| Vinay Garg | |||
| Aditya Sikand | |||
| P2860 | cites work | Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology | Q29547464 |
| Decreased heart rate variability and its association with increased mortality after acute myocardial infarction | Q34191387 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice | Q35952522 | ||
| Low Heart Rate Variability in a 2-Minute Electrocardiogram Recording Is Associated with an Increased Risk of Sudden Cardiac Death in the General Population: The Atherosclerosis Risk in Communities Study | Q36110158 | ||
| The role of the autonomic nervous system in sudden cardiac death. | Q37161633 | ||
| Sympathetic nervous system activation in human heart failure: clinical implications of an updated model | Q37560219 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| Parasympathetic failure and risk of subsequent coronary events in unstable angina and non-ST-segment elevation myocardial infarction | Q47679387 | ||
| Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity | Q49960457 | ||
| Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability | Q50089084 | ||
| A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity | Q50130800 | ||
| Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. | Q51246581 | ||
| Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale | Q58788709 | ||
| SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review | Q63071416 | ||
| Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction | Q64105820 | ||
| Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. | Q65000948 | ||
| Regression of left ventricular hypertrophy in diabetic nephropathy: loss of parasympathetic function predicts response to treatment | Q83317177 | ||
| SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection | Q90095373 | ||
| Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System? | Q90107415 | ||
| Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | Q90176149 | ||
| Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | Q91213372 | ||
| Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial | Q92754637 | ||
| Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | Q92980564 | ||
| Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes | Q93055906 | ||
| SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus | Q93062455 | ||
| Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors | Q93229030 | ||
| P921 | main subject | type 2 diabetes | Q3025883 |
| empagliflozin | Q5373824 | ||
| P304 | page(s) | 100039 | |
| P577 | publication date | 2020-06-21 | |
| P1433 | published in | Metabolism open | Q96319425 |
| P1476 | title | Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis | |
| P478 | volume | 7 |
Search more.